Hasegawa, S.; Kobayashi, N.; Wild, D.; Kaul, F.; Okubo, N.; Suzuki, A.; Kurita, Y.; Takano, S.; Nakajima, A.; Ichikawa, Y.
Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers 2022, 14, 3317.
https://doi.org/10.3390/cancers14143317
AMA Style
Hasegawa S, Kobayashi N, Wild D, Kaul F, Okubo N, Suzuki A, Kurita Y, Takano S, Nakajima A, Ichikawa Y.
Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers. 2022; 14(14):3317.
https://doi.org/10.3390/cancers14143317
Chicago/Turabian Style
Hasegawa, Sho, Noritoshi Kobayashi, Damian Wild, Fesupplix Kaul, Naoki Okubo, Akihiro Suzuki, Yusuke Kurita, Shoko Takano, Atsushi Nakajima, and Yasushi Ichikawa.
2022. "Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors" Cancers 14, no. 14: 3317.
https://doi.org/10.3390/cancers14143317
APA Style
Hasegawa, S., Kobayashi, N., Wild, D., Kaul, F., Okubo, N., Suzuki, A., Kurita, Y., Takano, S., Nakajima, A., & Ichikawa, Y.
(2022). Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers, 14(14), 3317.
https://doi.org/10.3390/cancers14143317